Lupus & antiphospholipid syndrome
Prevalence and clinical value of autoantibodies directed against lysobisphosphatidic acid in antiphospholipid syndrome
Authors' conclusion
The combined assay of aLBPA and conventional aPL could be used to stratify patients with persistent aPL.
Study context
- Population
- Patients with persistent conventional aPLs and aPL-negative controls91 with persistent aPL
- Participants
- 60 / 31 / 33
- Exposure
- Persistent aPL vs aPL-negative controls
- Symptomaticn = 60
- Asymptomaticn = 31
- Controlsn = 33reference
- Outcome
- Prevalence of against lysobisphophatidic acid (aLBPA)
Methodological detailsin-house enzyme-linked immunosorbent assay (ELISA)
- In-house ELISA
Main finding
As reported in the abstract
- Persistent aPL vs Controls: P < 0.0001
- Asymptomatic vs Symptomatic: P = 0.027
Observational data: associations, not effects.
Further findings
Clinical events suggestive of APS by aPL isotype
- Patients positive for IgG aPL alone had a greater likelihood of clinical events suggestive of APS
Original publication
Prevalence and clinical value of autoantibodies directed against lysobisphosphatidic acid in antiphospholipid syndrome. Rheumatology (Oxford). Published 23 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →